Singapore markets closed
Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,613.98 +281.23 (+0.42%) CMC Crypto 200
1,423.22 -5.35 (-0.37%)
Biogen Inc. (BIIB.MX)
Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
At close: 01:55PM CST
| Previous close | 3,714.53 |
| Open | 0.00 |
| Bid | 3,550.00 x 100 |
| Ask | 0.00 x 100 |
| Day's range | 3,714.53 - 3,714.53 |
| 52-week range | 3,286.00 - 5,393.00 |
| Volume | |
| Avg. volume | 67 |
| Market cap | 557.581B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 27.25 |
| EPS (TTM) | 136.32 |
| Earnings date | 23 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
BenzingaEurope Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND). SOD1-ALS is an ultra-rare genetic form of ALS estimated to affe
ZacksRepligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksBiogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
© 2024 Yahoo. All rights reserved.